<p>Terns Pharmaceuticals, Inc.（納斯達克代碼：TERN - 獲取免費報告）獲得了覆蓋該公司的十五位分析師的共識推薦為 “持有”，MarketBeat.com 報道稱。一位股票研究分析師給予該股票 “賣出” 評級，十位分析師給予 “持有” 評級，三位分析師給予 “買入” 評級，還有一位分析師給予 “強烈買入” 評級。在過去一年中，覆蓋該股票的經紀人給出的平均一年目標價格為 55.1364 美元。</p>
<p>獲取 <strong>Terns Pharmaceuticals</strong> 的提醒：</p>
<p>TERN 已成為多份研究報告的主題。威廉·布萊爾在 4 月 7 日的報告中將 Terns Pharmaceuticals 的股票評級從 “強烈買入” 下調至 “持有”。公民 Jmp 在 3 月 26 日的報告中將 Terns Pharmaceuticals 的股票評級從 “市場表現優於大盤” 下調至 “持有”。BMO Capital Markets 在 3 月 26 日的報告中將 Terns Pharmaceuticals 的股票評級從 “強烈買入” 下調至 “持有”。TD Cowen 在 3 月 26 日的報告中將 Terns Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”，並設定了 53.00 美元的目標價格。最後，Weiss Ratings 在 3 月 27 日的報告中重新發布了 Terns Pharmaceuticals 的 “賣出（e+）” 評級。</p>
<p><strong>查看我們最新的 Terns Pharmaceuticals 股票報告</strong></p>
<h2>內部人士下注</h2>
<p>在其他消息中，首席執行官艾米·L·巴羅（Amy L. Burroughs）在 3 月 16 日的交易中出售了 14,583 股公司的股票。股票以平均價格 46.71 美元出售，總價值為 681,171.93 美元。出售後，首席執行官直接持有 288,976 股公司的股票，價值約為 13,498,068.96 美元。這代表其持股比例下降了 4.80%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。此外，內部人士埃米爾·庫里亞科斯（Emil Kuriakose）在 4 月 1 日的交易中出售了 942 股公司的股票。股票以平均價格 52.75 美元出售，總交易額為 49,690.50 美元。出售完成後，該內部人士直接持有 105,673 股公司股票，價值約為 5,574,250.75 美元。這代表其持股比例下降了 0.88%。該交易的披露信息可在 SEC 文件中找到。在過去的九十天裏，內部人士出售了價值 1,302,370 美元的 30,108 股公司股票。內部人士持有公司股票的比例為 1.50%。</p>
<h2>機構投資者對 Terns Pharmaceuticals 的看法</h2>
<p>一些機構投資者最近調整了對公司的持股。摩根士丹利在第四季度將其在 Terns Pharmaceuticals 的股份增加了 4.7%。摩根士丹利目前持有 7,945,608 股公司股票，價值 321,003,000 美元，此前在上個季度購買了額外的 356,513 股。Commodore Capital LP 在第三季度購買了價值 42,807,000 美元的 Terns Pharmaceuticals 新股份。Adage Capital Partners GP L.L.C. 在第四季度將其在 Terns Pharmaceuticals 的股份增加了 40.9%。Adage Capital Partners GP L.L.C. 目前持有 5,550,000 股公司股票，價值 224,220,000 美元，此前在上個季度購買了額外的 1,611,000 股。先鋒集團（Vanguard Group Inc.）在第四季度將其在 Terns Pharmaceuticals 的股份增加了 21.1%。先鋒集團目前持有 5,523,948 股公司股票，價值 223,167,000 美元，此前在上個季度購買了額外的 964,031 股。最後，Vestal Point Capital LP 在第四季度購買了價值 181,800,000 美元的 Terns Pharmaceuticals 新股份。98.26% 的股票由機構投資者持有。</p>
<h2>Terns Pharmaceuticals 價格表現</h2>
<p>TERN 週二開盤價為 52.97 美元。Terns Pharmaceuticals 的 52 周低點為 2.65 美元，52 周高點為 53.19 美元。該公司的市值為 61.2 億美元，市盈率為 -51.42，貝塔值為 -0.37。公司的 50 日移動平均價格為 48.93 美元，200 日移動平均價格為 36.96 美元。</p>
<p>Terns Pharmaceuticals（納斯達克代碼：TERN - 獲取免費報告）最後一次發佈財報是在 3 月 30 日，報告顯示該公司本季度每股收益為（0.24）美元，超出分析師共識預期的（0.30）美元 0.06 美元。作為一個整體，股票研究分析師預測 Terns Pharmaceuticals 在本年度將發佈 -1.21 的每股收益。</p>
<h2>關於 Terns Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Terns Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於開發用於治療慢性肝病和其他嚴重疾病的口服小分子療法。該公司的研發工作集中在旨在解決進展性肝病的根本原因的新機制上，包括炎症、纖維化和代謝失調。通過推進可以口服給藥的靶向化合物，Terns 旨在為患者提供比注射或生物療法更方便和有效的治療選擇。</p>
<p>該公司的產品管線包含多個處於不同臨牀和前臨牀評估階段的候選藥物。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Terns Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBURZTeW1ib2w9VEVSTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBURZTeW1ib2w9VEVSTg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Terns Pharmaceuticals 嗎？</h2>
<p>在你考慮投資 Terns Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及他們推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Terns Pharmaceuticals 並不在名單上。</p>
<p>雖然 Terns Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TERN

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

標普生物技術 3 倍做多 - Direxion

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

<p>Terns Pharmaceuticals, Inc.（納斯達克代碼：TERN）獲得了十五位分析師的 “持有” 共識推薦。具體分佈為一位賣出、十位持有、三位買入和一位強烈買入推薦。平均一年目標價為 55.14 美元。近期內部人士交易包括首席執行官 Amy L. Burroughs 出售了 14,583 股，Emil Kuriakose 出售了 942 股。機構投資者持有 98.26% 的股份。Terns 的市值為 61.2 億美元，報告每股收益為（0.24 美元），超出預期。該股票開盤價為 52.97 美元，52 周價格區間為 2.65 美元至 53.19 美元</p>

<p>Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has earned a consensus recommendation of &#34;Hold&#34; from the fifteen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $55.1364.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals, Inc.（納斯達克代碼：TERN - 獲取免費報告）獲得了覆蓋該公司的十五位分析師的共識推薦為 “持有”，MarketBeat.com 報道稱。一位股票研究分析師給予該股票 “賣出” 評級，十位分析師給予 “持有” 評級，三位分析師給予 “買入” 評級，還有一位分析師給予 “強烈買入” 評級。在過去一年中，覆蓋該股票的經紀人給出的平均一年目標價格為 55.1364 美元。</p>
</div><p>Get <strong>Terns Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Terns Pharmaceuticals</strong> 的提醒：</p>
</div><p>TERN has been the topic of a number of research reports. William Blair lowered shares of Terns Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, April 7th. Citizens Jmp lowered shares of Terns Pharmaceuticals from a &#34;market outperform&#34; rating to a &#34;hold&#34; rating in a report on Thursday, March 26th. BMO Capital Markets lowered shares of Terns Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, March 26th. TD Cowen lowered shares of Terns Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $53.00 target price on the stock. in a report on Thursday, March 26th. Finally, Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Terns Pharmaceuticals in a report on Friday, March 27th.</p>
<div class="lb-trans"><p>TERN 已成為多份研究報告的主題。威廉·布萊爾在 4 月 7 日的報告中將 Terns Pharmaceuticals 的股票評級從 “強烈買入” 下調至 “持有”。公民 Jmp 在 3 月 26 日的報告中將 Terns Pharmaceuticals 的股票評級從 “市場表現優於大盤” 下調至 “持有”。BMO Capital Markets 在 3 月 26 日的報告中將 Terns Pharmaceuticals 的股票評級從 “強烈買入” 下調至 “持有”。TD Cowen 在 3 月 26 日的報告中將 Terns Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”，並設定了 53.00 美元的目標價格。最後，Weiss Ratings 在 3 月 27 日的報告中重新發布了 Terns Pharmaceuticals 的 “賣出（e+）” 評級。</p>
</div><p><strong>View Our Latest Stock Report on Terns Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Terns Pharmaceuticals 股票報告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, CEO Amy L. Burroughs sold 14,583 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the sale, the chief executive officer directly owned 288,976 shares of the company's stock, valued at approximately $13,498,068.96. This represents a 4.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Emil Kuriakose sold 942 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total transaction of $49,690.50. Following the completion of the sale, the insider directly owned 105,673 shares in the company, valued at approximately $5,574,250.75. This represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 30,108 shares of company stock worth $1,302,370. Insiders own 1.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席執行官艾米·L·巴羅（Amy L. Burroughs）在 3 月 16 日的交易中出售了 14,583 股公司的股票。股票以平均價格 46.71 美元出售，總價值為 681,171.93 美元。出售後，首席執行官直接持有 288,976 股公司的股票，價值約為 13,498,068.96 美元。這代表其持股比例下降了 4.80%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。此外，內部人士埃米爾·庫里亞科斯（Emil Kuriakose）在 4 月 1 日的交易中出售了 942 股公司的股票。股票以平均價格 52.75 美元出售，總交易額為 49,690.50 美元。出售完成後，該內部人士直接持有 105,673 股公司股票，價值約為 5,574,250.75 美元。這代表其持股比例下降了 0.88%。該交易的披露信息可在 SEC 文件中找到。在過去的九十天裏，內部人士出售了價值 1,302,370 美元的 30,108 股公司股票。內部人士持有公司股票的比例為 1.50%。</p>
</div><h2>Institutional Investors Weigh In On Terns Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Terns Pharmaceuticals 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of the company. Morgan Stanley boosted its stake in shares of Terns Pharmaceuticals by 4.7% in the 4th quarter. Morgan Stanley now owns 7,945,608 shares of the company's stock valued at $321,003,000 after purchasing an additional 356,513 shares during the last quarter. Commodore Capital LP bought a new stake in shares of Terns Pharmaceuticals in the 3rd quarter valued at $42,807,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of Terns Pharmaceuticals by 40.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,550,000 shares of the company's stock valued at $224,220,000 after purchasing an additional 1,611,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Terns Pharmaceuticals by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 5,523,948 shares of the company's stock valued at $223,167,000 after purchasing an additional 964,031 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Terns Pharmaceuticals in the 4th quarter valued at $181,800,000. 98.26% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者最近調整了對公司的持股。摩根士丹利在第四季度將其在 Terns Pharmaceuticals 的股份增加了 4.7%。摩根士丹利目前持有 7,945,608 股公司股票，價值 321,003,000 美元，此前在上個季度購買了額外的 356,513 股。Commodore Capital LP 在第三季度購買了價值 42,807,000 美元的 Terns Pharmaceuticals 新股份。Adage Capital Partners GP L.L.C. 在第四季度將其在 Terns Pharmaceuticals 的股份增加了 40.9%。Adage Capital Partners GP L.L.C. 目前持有 5,550,000 股公司股票，價值 224,220,000 美元，此前在上個季度購買了額外的 1,611,000 股。先鋒集團（Vanguard Group Inc.）在第四季度將其在 Terns Pharmaceuticals 的股份增加了 21.1%。先鋒集團目前持有 5,523,948 股公司股票，價值 223,167,000 美元，此前在上個季度購買了額外的 964,031 股。最後，Vestal Point Capital LP 在第四季度購買了價值 181,800,000 美元的 Terns Pharmaceuticals 新股份。98.26% 的股票由機構投資者持有。</p>
</div><h2>Terns Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Terns Pharmaceuticals 價格表現</h2>
</div><p>TERN opened at $52.97 on Tuesday. Terns Pharmaceuticals has a fifty-two week low of $2.65 and a fifty-two week high of $53.19. The firm has a market capitalization of $6.12 billion, a price-to-earnings ratio of -51.42 and a beta of -0.37. The company's 50 day moving average price is $48.93 and its two-hundred day moving average price is $36.96.</p>
<div class="lb-trans"><p>TERN 週二開盤價為 52.97 美元。Terns Pharmaceuticals 的 52 周低點為 2.65 美元，52 周高點為 53.19 美元。該公司的市值為 61.2 億美元，市盈率為 -51.42，貝塔值為 -0.37。公司的 50 日移動平均價格為 48.93 美元，200 日移動平均價格為 36.96 美元。</p>
</div><p>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06. As a group, equities research analysts predict that Terns Pharmaceuticals will post -1.21 EPS for the current year.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals（納斯達克代碼：TERN - 獲取免費報告）最後一次發佈財報是在 3 月 30 日，報告顯示該公司本季度每股收益為（0.24）美元，超出分析師共識預期的（0.30）美元 0.06 美元。作為一個整體，股票研究分析師預測 Terns Pharmaceuticals 在本年度將發佈 -1.21 的每股收益。</p>
</div><h2>About Terns Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Terns Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於開發用於治療慢性肝病和其他嚴重疾病的口服小分子療法。該公司的研發工作集中在旨在解決進展性肝病的根本原因的新機制上，包括炎症、纖維化和代謝失調。通過推進可以口服給藥的靶向化合物，Terns 旨在為患者提供比注射或生物療法更方便和有效的治療選擇。</p>
</div><p>The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.</p>
<div class="lb-trans"><p>該公司的產品管線包含多個處於不同臨牀和前臨牀評估階段的候選藥物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Terns Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Terns Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TERN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Terns Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Terns Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Terns Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Terns Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及他們推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Terns Pharmaceuticals 並不在名單上。</p>
</div><p>While Terns Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Terns Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Hold" from Analysts

Market Beat

Terns Pharmaceuticals

蒙特利爾銀行

Toronto Dominion Bank

摩根士丹利

The Vanguard Group, Inc.

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Terns Pharmaceuticals, Inc.（納斯達克股票代碼：TERN）被分析師給予 “持有” 的平均建議